Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

NCT ID: NCT02304484

Last Updated: 2019-03-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

770 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-24

Study Completion Date

2018-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Evolocumab

Participants received 420 mg evolocumab once a month for up to 2 years.

Group Type EXPERIMENTAL

Evolocumab

Intervention Type BIOLOGICAL

Administered by subcutaneous injection once a month

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evolocumab

Administered by subcutaneous injection once a month

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AMG 145 Repatha

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Completed week 80 of study 20120153 (NCT01813422).

Exclusion Criteria

* Did not complete investigational product in the 20120153 parent study
* Have an unstable medical condition, in the judgment of the investigator
* Known sensitivity to any of the products to be administered during dosing
* Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Huntsville, Alabama, United States

Site Status

Research Site

Mobile, Alabama, United States

Site Status

Research Site

Long Beach, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

Torrance, California, United States

Site Status

Research Site

Jacksonville, Florida, United States

Site Status

Research Site

Munster, Indiana, United States

Site Status

Research Site

Lexington, Kentucky, United States

Site Status

Research Site

Covington, Louisiana, United States

Site Status

Research Site

Bethesda, Maryland, United States

Site Status

Research Site

Columbia, Maryland, United States

Site Status

Research Site

Bay City, Michigan, United States

Site Status

Research Site

Midland, Michigan, United States

Site Status

Research Site

Duluth, Minnesota, United States

Site Status

Research Site

Saint Cloud, Minnesota, United States

Site Status

Research Site

Columbia, Missouri, United States

Site Status

Research Site

Ridgewood, New Jersey, United States

Site Status

Research Site

Fargo, North Dakota, United States

Site Status

Research Site

Canton, Ohio, United States

Site Status

Research Site

Toledo, Ohio, United States

Site Status

Research Site

Oak Ridge, Tennessee, United States

Site Status

Research Site

Amarillo, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Wichita Falls, Texas, United States

Site Status

Research Site

La Plata, Buenos Aires, Argentina

Site Status

Research Site

Córdoba, Córdoba Province, Argentina

Site Status

Research Site

Córdoba, , Argentina

Site Status

Research Site

Córdoba, , Argentina

Site Status

Research Site

Liverpool, New South Wales, Australia

Site Status

Research Site

New Lambton Heights, New South Wales, Australia

Site Status

Research Site

Chermside, Queensland, Australia

Site Status

Research Site

Herston, Queensland, Australia

Site Status

Research Site

Adelaide, South Australia, Australia

Site Status

Research Site

Fullarton, South Australia, Australia

Site Status

Research Site

Epping, Victoria, Australia

Site Status

Research Site

Footscray, Victoria, Australia

Site Status

Research Site

Nedlands, Western Australia, Australia

Site Status

Research Site

Antwerp, , Belgium

Site Status

Research Site

Edegem, , Belgium

Site Status

Research Site

Genk, , Belgium

Site Status

Research Site

Hasselt, , Belgium

Site Status

Research Site

Lodelinsart, , Belgium

Site Status

Research Site

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Research Site

São Paulo, , Brazil

Site Status

Research Site

Calgary, Alberta, Canada

Site Status

Research Site

Victoria, British Columbia, Canada

Site Status

Research Site

Winnipeg, Manitoba, Canada

Site Status

Research Site

St. John's, Newfoundland and Labrador, Canada

Site Status

Research Site

Halifax, Nova Scotia, Canada

Site Status

Research Site

London, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Laval, Quebec, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Québec, Quebec, Canada

Site Status

Research Site

Temuco, Cautín, Chile

Site Status

Research Site

Brno, , Czechia

Site Status

Research Site

Hradec Králové, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Zlín, , Czechia

Site Status

Research Site

Besançon, , France

Site Status

Research Site

Chambray-lès-Tours, , France

Site Status

Research Site

Marseille, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Pessac, , France

Site Status

Research Site

Essen, , Germany

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Heraklion, , Greece

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Debrecen, , Hungary

Site Status

Research Site

Szeged, , Hungary

Site Status

Research Site

Reykjavik, , Iceland

Site Status

Research Site

Galway, , Ireland

Site Status

Research Site

Hadera, , Israel

Site Status

Research Site

Jerusalem, , Israel

Site Status

Research Site

Novara, , Italy

Site Status

Research Site

Rozzano MI, , Italy

Site Status

Research Site

Sesto San Giovanni (MI), , Italy

Site Status

Research Site

Torino, , Italy

Site Status

Research Site

Kuantan, Pahang, Malaysia

Site Status

Research Site

George Town, , Malaysia

Site Status

Research Site

Guadalajara, Jalisco, Mexico

Site Status

Research Site

San Luis Potosí City, San Luis Potosí, Mexico

Site Status

Research Site

Culiacán, Sinaloa, Mexico

Site Status

Research Site

Aguascalientes, , Mexico

Site Status

Research Site

Alkmaar, , Netherlands

Site Status

Research Site

Amsterdam, , Netherlands

Site Status

Research Site

Amsterdam, , Netherlands

Site Status

Research Site

Leeuwarden, , Netherlands

Site Status

Research Site

Nijmegen, , Netherlands

Site Status

Research Site

Rotterdam, , Netherlands

Site Status

Research Site

Tilburg, , Netherlands

Site Status

Research Site

Utrecht, , Netherlands

Site Status

Research Site

Zwolle, , Netherlands

Site Status

Research Site

Oslo, , Norway

Site Status

Research Site

Chrzanów, , Poland

Site Status

Research Site

Kędzierzyn-Koźle, , Poland

Site Status

Research Site

Krakow, , Poland

Site Status

Research Site

Krakow, , Poland

Site Status

Research Site

Lodz, , Poland

Site Status

Research Site

Warsaw, , Poland

Site Status

Research Site

Kemerovo, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Centurion, Gauteng, South Africa

Site Status

Research Site

Sunninghill, Gauteng, South Africa

Site Status

Research Site

Kuils River, Western Cape, South Africa

Site Status

Research Site

Daejeon, , South Korea

Site Status

Research Site

Seongnam-si, Gyeonggi-do, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Málaga, Andalusia, Spain

Site Status

Research Site

Barcelona, Catalonia, Spain

Site Status

Research Site

L'Hospitalet de Llobregat, Catalonia, Spain

Site Status

Research Site

Gijón, Principality of Asturias, Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Gothenburg, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Geneva, , Switzerland

Site Status

Research Site

New Taipei City, , Taiwan

Site Status

Research Site

Newcastle upon Tyne, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil Canada Chile Czechia France Germany Greece Hungary Iceland Ireland Israel Italy Malaysia Mexico Netherlands Norway Poland Russia South Africa South Korea Spain Sweden Switzerland Taiwan United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-001524-30

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

20140128

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.